Imlunestrant Tosylate Drug Asset Due Diligence Report 2026

This Imlunestrant Tosylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

100

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Imlunestrant Tosylate can convert its Small molecule drug profile and ER biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Imlunestrant Tosylate (query alias: imlunestrant)
Modality / target	Small molecule drug; ER; ERs degraders
Highest global status	Approved
Originator	Eli Lilly & Co.
Active developers	Eli Lilly & Co., Eli Lilly Nederland BV, Eli Lilly Japan KK

The MCP disease footprint includes ER-positive/HER2-negative/ ESR1-mutated breast cancer, ER-positive/HER2-negative Breast Cancer, Advanced breast cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07287098	Phase 2	Recruiting	600	Change from Baseline in Antigen Kiel (Ki-67) Expression
NCT07410559	Phase 2	Not yet recruiting	189	ORR between Arm A and Arm B
JPRN-jRCTs031260249	Phase 2	募集前	132	無増悪生存期間（PFS）：主たる解析対象集団を対象とし、無作為化日からPD又は理由を問わない死亡日のうち早い方までの期間とする。効果判定は、Response Evaluation Criteria in Solid Tumors （RECIST） Ver.1.1に準じて評価する。

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Safety profile of post-CDK4/6 treatments in HR+/HER2− metastatic breast cancer (mBC): A network meta-analysis

Phase 2/3; n=16; evaluation: Positive. Reported fields: AE(Grade ≥3) = 2.76 RR ; AE(Grade ≥3) = 0.47 RR ; -

Circulating Tumour DNA (ctDNA) Dynamics From Patients With ER+, HER2- Advanced Breast Cancer in the Phase 3 EMBER-3 Trial

Phase 3; n=635; evaluation: Positive. Reported fields: VAF(did not achieve a ≥50% reduction in ctDNA from baseline to C2D1; PFS) = 58.0 % ; -; -

Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial

Phase 3; n=874; evaluation: Positive. Reported fields: mPFS = 3.9 month (95%CI, 3.7 - 5.5); mPFS = 5.5 month (95%CI, 3.8 - 5.6); mPFS = 3.8 month (95%CI, 3.7 - 5.5)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Imlunestrant Tosylate addresses ER-positive/HER2-negative/ ESR1-mutated breast cancer, ER-positive/HER2-negative Breast Cancer, Advanced breast cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 100 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: ER records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-30	Estrigenix Therapeutics Secures Exclusive License Agreement for Novel Menopause Therapeutics Platform	Preclinical	Financial terms not disclosed
2026-05-12	Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)	Approved	US$70.0M upfront; US$335.0M milestones
2026-03-31	LG Chem to develop and commercialize Mochida Pharmaceutical's Dinagest against endometriosis in South Korea and Thailand	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Treatment of cancer with an AKT1 inhibitor”. The milestone feed surfaced a patent-application signal described as “Combination therapy for the treatment of cancer”. The milestone feed surfaced a patent-application signal described as “ESR1 gene fusions and uses thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO